ArticleJournal of pain research2026
Efficacy, Safety, and Economic Evaluation of Gamidaeganghwal-Tang in Patients with Knee Osteoarthritis: Protocol for a Multicenter, Randomized, Double-Blind, Controlled Trial.
Article in Journal of pain research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Knee osteoarthritis (KOA) is a common degenerative joint disease that severely affects quality of life. Gamidaeganghwal-tang (GMDGHT), a traditional Korean herbal medicine, has been widely used to treat joint pain and stiffness. However, robust clinical evidence for its efficacy and safety is lacking. This trial protocol aims to evaluate the efficacy, safety, and cost-effectiveness of GMDGHT compared to a placebo in patients with degenerative KOA. Trial Design and Methods: This protocol describes a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial. A total of 160 participants (80 per group) will be recruited from four Korean medicine hospitals. Eligible participants aged 40-70 years must have radiographic KOA (Kellgren-Lawrence grades I-III) and a Korean Western Ontario and McMaster Universities Osteoarthritis Index (K-WOMAC) score ≥30. Participants will be randomly assigned 1:1 to receive either GMDGHT or placebo granules (10 g, orally, three times daily) for 12 weeks, followed by a 12-week observation period. Assessments will be conducted at baseline and at weeks 4, 8, 12, and 24. The primary outcome will be the change in total K-WOMAC score from baseline to week 12. Secondary outcomes include pain intensity (100-mm visual analog scale), quality of life using the EuroQol 5-dimension 5-level (EQ-5D-5L), patient satisfaction, rescue medication use, and cost-effectiveness from societal and healthcare perspectives. Safety will be monitored through adverse events and laboratory findings. Discussion: This trial will rigorously evaluate the efficacy, safety, and cost-effectiveness of GMDGHT for KOA. Despite efforts to maintain blinding with identically packaged placebo granules, subtle differences in taste or texture may challenge complete participant blinding. Restrictions on concomitant therapies may also influence adherence. Nonetheless, this study is designed to minimize potential bias and generate reliable clinical evidence on GMDGHT's role as a complementary or alternative therapeutic option for KOA. Trial Registration Number: KCT0008486 (Clinical Research Information Service of the Republic of Korea), registered on 01 June 2023. Ind Approval Number: 101414 (Approved by the Ministry of Food and Drug Safety, Republic of Korea) on April 19, 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.